Once-Daily Use of Colchicine in Children with Familial Mediterranean Fever

Abstract

Patients with familial Mediterranean fever routinely take daily multiple doses of colchicine to prevent acute attacks and to reduce the risk of amyloidosis. However, although there is no research in this regard in the literature, some clinicians believe that the use of colchicine in children as daily single dose may cause toxic side effects. The efficiency and the side effects of the administration of daily single dose versus daily multiple doses of colchicine were evaluated in the treatment of patients with familial Mediterranean fever. Thirty-nine patients being observed at Atatürk University Medical Faculty Pediatrics outpatient clinic with the diagnosis of familial Mediterranean fever were randomly divided into 2 groups. Group I consisted of 20 patients who continued taking colchicine in 2 or 3 divided doses daily as they did before the study. Group II comprised 19 patients who were given the total daily colchicine dose at 1 time. Patients were re-examined at 30-day intervals and both groups maintained this regimen for an average duration of 8 months. There was no difference between these 2 groups with respect to frequency of side effects, number of attacks, and acute phase response. Therefore, the daily colchicine dose can be given to children once daily.

Get full access to this article

View all access options for this article.

References

Sohar E , Gafni J , Pras M , Heller H . Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227-253.

Ozer FL , Kaplaman E , Zileli S . Familial Mediterranean fever in Turkey. A report of twenty cases. Am J Med. 1971;50:336-339.

Schwabe AD , Peters RS . Familial Mediterranean Fever in Armenians. Analysis of 100 cases. Medicine (Baltimore). 1974;53:453-462.

Barakat MH , Karnik AM , Majeed HW , el-Sobki NI , Fenech FF . Familial Mediterranean fever (recurrent hereditary polyserositis) in Arabs—a study of 175 patients and review of the literature. Q J Med. 1986;60:837-847.

Goldfinger SE . Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.

Zemer D , Revach M , Pras M , Modan B , Schor S , Sohar E , Gafni J . A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med. 1974;291:932-934.

Lehman TJ , Peters RS , Hanson V , Schwabe A . Long-term colchicine therapy of familial Mediterranean fever. J Pediatr. 1978;93:876-878.

Zemer D , Pras M , Sohar E , Modan M , Cabili S , Gafni J . Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001-1005.

Pras M . Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998;27:92-97.

10.

Famaey JP . Colchicine in therapy. State of the art and new perspectives for an old drug. Clin Exp Rheumatol. 1988;6:305-317.

11.

Levy M , Spino M , Read SE . Colchicine: a state-of-the-art review. Pharmacotherapy. 1991;11:196-211.

12.

Molad Y . Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252-256.

13.

Zemer D , Livneh A , Danon YL , Pras M , Sohar E . Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34:973-977.

14.

Dinarello CA , Wolff SM , Goldfinger SE , Dale DC , Alling DW . Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934-937.